42237-85-4

Usage

Uses

Used in Pharmaceutical Industry:
3-Amino-5-bromobenzoic acid is utilized as an intermediate in the synthesis of pharmaceuticals for its ability to contribute to the development of new drugs and medications. Its unique structure allows for the creation of compounds with specific therapeutic properties, making it a valuable component in drug discovery and design.
Used in Dye Industry:
In the dye industry, 3-Amino-5-bromobenzoic acid serves as a chemical intermediate for the production of various dyes. Its structural features enable the creation of dyes with distinct color characteristics, which are essential for a range of applications, including textiles, printing, and other industrial uses.
Used in Organic Synthesis:
3-Amino-5-bromobenzoic acid is employed as a versatile building block in organic synthesis. Its reactivity and functional groups make it suitable for the preparation of a wide array of organic compounds, which can be further utilized in various chemical and industrial processes.
Used in Medicinal Chemistry Research:
3-Amino-5-bromobenzoic acid is used as a research compound in medicinal chemistry. Its unique structure and properties make it an attractive candidate for studying the interactions between biological molecules and potential drug candidates, thereby aiding in the advancement of pharmaceutical science and the development of novel therapeutic agents.

Upstream product

• 6307-83-1 3-bromo-5-nitro-benzoic acid 
• 5326-49-8 N-(3-bromo-5-methylphenyl)acetamide 
• 121-92-6 3-nitrobenzoic acid 
• 78238-11-6 3-bromo-5-acetylaminobenzoic acid 

Downstream Products

• 618-58-6 3,5-dibromobenzoic acid 
• 1585969-88-5 methyl 3-([1,1'-biphenyl]-4-ylcarboxamido)-5-bromobenzoate 
• 1585969-80-7 3-([1,1'-biphenyl]-4-ylcarboxamido)-5-bromobenzoic acid 
• 1229442-64-1 ethyl 3-(cyclopropylmethoxy)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate 
• 1229442-63-0 ethyl 3-bromo-5-(cyclopropylmethoxy)benzoate 
• 870673-35-1 3-bromo-5-hydroxybenzoic acid ethyl ester 
• 1229442-69-6 ethyl 3-ethoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate 
• 1229442-68-5 ethyl 3-bromo-5-ethoxybenzoate 
• 1229441-19-3 5-(cyclopropylmethoxy)-3'-(5-(3-(3,5-dichloropyridin-4-yl)ureido)-1-ethyl-6-oxo-1,6-dihydropyridazin-3-yl)-N-(2-(piperidin-1-yl)ethyl)-[1,1'-biphenyl]-3-carboxamide 
• 1229441-31-9 N-cyclopropyl-3'-(5-(3-(3,5-dichloropyridin-4-yl)ureido)-1-ethyl-6-oxo-1,6-dihydropyridazin-3-yl)-5-ethoxy-[1,1'-biphenyl]-3-carboxamide 
• 1229441-17-1 5-(cyclopropylmethoxy)-3'-(5-(3-(3,5-dichloropyridin-4-yl)ureido)-1-ethyl-6-oxo-1,6-dihydropyridazin-3-yl)-[1,1'-biphenyl]-3-carboxylic acid 
• 1229441-16-0 ethyl 5-(cyclopropylmethoxy)-3'-(5-(3-(3,5-dichloropyridin-4-yl)ureido)-1-ethyl-6-oxo-1,6-dihydropyridazin-3-yl)-[1,1'-biphenyl]-3-carboxylate 

Relevant academic research and scientific papers

Biphenyl Pyridazinone Derivatives as Inhaled PDE4 Inhibitors: Structural Biology and Structure-Activity Relationships

Cyclic nucleotide cAMP is a ubiquitous secondary messenger involved in a plethora of cellular responses to biological agents involving activation of adenylyl cyclase. Its intracellular levels are tightly controlled by a family of cyclic nucleotide degrading enzymes, the PDEs. In recent years, cyclic nucleotide phosphodiesterase type 4 (PDE4) has aroused scientific attention as a suitable target for anti-inflammatory therapy in respiratory diseases, particularly in the management of asthma and COPD. Here we describe our efforts to discover novel, highly potent inhaled inhibitors of PDE4. Through structure based design, with the inclusion of a variety of functional groups and physicochemical profiles in order to occupy the solvent-filled pocket of the PDE4 enzyme, we modified the structure of our oral PDE4 inhibitors to reach compounds down to picomolar enzymatic potencies while at the same time tackling successfully an uncovered selectivity issue with the adenosine receptors. In vitro potencies were demonstrated in a rat lung neutrophilia model by administration of a suspension with a Penn-Century MicroSprayer Aerosolizer.

3-(5-Amino-6-oxo-1,6-dihydropyridazin-3-yl)-biphenyl derivatives as PDE4 inhibitors

New pyridazin-3(2H)-one derivatives having the chemical structure of formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of the phosphodiesterase IV (PDE4).

(3-oxo)pyridazin-4-ylurea derivatives as PDE4 inhibitors

New (3-oxo)pyridazin-4-ylurea derivatives having the chemcial structure of formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of the phosphodiesterase IV (PDE4).

Oligofunctional amphiphiles featuring geometric core group preorganization: Synthesis and study of Langmuir and Langmuir-Blodgett films

Based on the principle of supramolecular preorganization, a new type of oligofunctional amphiphile, of which compounds 1-4 are representative structures, has been designed and synthesized. The typical feature of their structure is a highly rigid and geometrically well-defined central unit composed of ethynylene substituted aromatic spacers with different numbers of amphiphilic segment groups (also of a rigid geometric design) attached to it. The molecules form well-defined Langmuir films when spread from a solution at the air/water interface or when a 10-4 M aqueous CaCl2 solution was used as the subphase. By analysis of the surface pressure-surface area (π-A) isotherms, information on the packing behavior and orientation of the amphiphilic molecules depending on the molecular structure could be obtained. Morphological characterization of the dynamic process of monolayer compression at the air/water interface was carried out by Brewster angle microscopy, illustrating several phase states visualized as snap shots. Thin monolayer films produced on a 10-4 M aqueous CaCl2 subphase can be transferred to a mica solid support by the Langmuir-Blodgett technique. Tapping mode atomic force microscopy reveals a surface topography of the monofilms composed of 1 and 3 that differ in roughness and also in the properties of elasticity, hardness and adhesive strength. X-Ray crystal structure analysis of three relevant intermediate compounds of the synthesis were successfully determined giving an indication of the potential structural features inherent in the new amphiphiles. The Royal Society of Chemistry 2005.